Cargando…
The efficacy and safety of quinagolide in hyperprolactinemia treatment: A systematic review and meta-analysis
PURPOSE: Three dopamine agonists [bromocriptine, cabergoline, and quinagolide (CV)] have been used for hyperprolactinemia treatment for decades. Several studies have reviewed the efficacy and safety of bromocriptine and cabergoline. However, no systematic review or meta-analysis has discussed the ef...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9902948/ https://www.ncbi.nlm.nih.gov/pubmed/36761195 http://dx.doi.org/10.3389/fendo.2023.1027905 |
_version_ | 1784883370469097472 |
---|---|
author | Zeng, Yanyang Huang, Qingliang Zou, Yunzhi Tan, Jiacong Zhou, Wu Li, Meihua |
author_facet | Zeng, Yanyang Huang, Qingliang Zou, Yunzhi Tan, Jiacong Zhou, Wu Li, Meihua |
author_sort | Zeng, Yanyang |
collection | PubMed |
description | PURPOSE: Three dopamine agonists [bromocriptine, cabergoline, and quinagolide (CV)] have been used for hyperprolactinemia treatment for decades. Several studies have reviewed the efficacy and safety of bromocriptine and cabergoline. However, no systematic review or meta-analysis has discussed the efficacy and safety of CV in hyperprolactinemia and prolactinoma treatment. METHODS: Five medical databases (PubMed, Web of Science, Embase, Scopus, and Cochrane Library) were searched up to 9 May 2022 to identify studies related to CV and hyperprolactinemia. A meta-analysis was implemented by using a forest plot, funnel plot, sensitivity analysis, meta-regression, and Egger’s test via software R 4.0 and STATA 12. RESULTS: A total of 1,211 studies were retrieved from the five medical databases, and 33 studies consisting of 827 patients were finally included in the analysis. The pooled proportions of patients with prolactin concentration normalization and tumor reduction (>50%) under CV treatment were 69% and 20%, respectively, with 95% confidence intervals of 61%–76% and 15%–28%, respectively. The pooled proportion of adverse effects was 13%, with a 95% confidence interval of 11%–16%. CONCLUSION: Our study showed that CV is not less effective than cabergoline and bromocriptine in treating hyperprolactinemia, and the side effects were not significant. Hence, this drug could be considered an alternative first-line or rescue treatment in treating hyperprolactinemia in the future. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/PROSPERO, identifier CRD42022347750. |
format | Online Article Text |
id | pubmed-9902948 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-99029482023-02-08 The efficacy and safety of quinagolide in hyperprolactinemia treatment: A systematic review and meta-analysis Zeng, Yanyang Huang, Qingliang Zou, Yunzhi Tan, Jiacong Zhou, Wu Li, Meihua Front Endocrinol (Lausanne) Endocrinology PURPOSE: Three dopamine agonists [bromocriptine, cabergoline, and quinagolide (CV)] have been used for hyperprolactinemia treatment for decades. Several studies have reviewed the efficacy and safety of bromocriptine and cabergoline. However, no systematic review or meta-analysis has discussed the efficacy and safety of CV in hyperprolactinemia and prolactinoma treatment. METHODS: Five medical databases (PubMed, Web of Science, Embase, Scopus, and Cochrane Library) were searched up to 9 May 2022 to identify studies related to CV and hyperprolactinemia. A meta-analysis was implemented by using a forest plot, funnel plot, sensitivity analysis, meta-regression, and Egger’s test via software R 4.0 and STATA 12. RESULTS: A total of 1,211 studies were retrieved from the five medical databases, and 33 studies consisting of 827 patients were finally included in the analysis. The pooled proportions of patients with prolactin concentration normalization and tumor reduction (>50%) under CV treatment were 69% and 20%, respectively, with 95% confidence intervals of 61%–76% and 15%–28%, respectively. The pooled proportion of adverse effects was 13%, with a 95% confidence interval of 11%–16%. CONCLUSION: Our study showed that CV is not less effective than cabergoline and bromocriptine in treating hyperprolactinemia, and the side effects were not significant. Hence, this drug could be considered an alternative first-line or rescue treatment in treating hyperprolactinemia in the future. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/PROSPERO, identifier CRD42022347750. Frontiers Media S.A. 2023-01-24 /pmc/articles/PMC9902948/ /pubmed/36761195 http://dx.doi.org/10.3389/fendo.2023.1027905 Text en Copyright © 2023 Zeng, Huang, Zou, Tan, Zhou and Li https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Endocrinology Zeng, Yanyang Huang, Qingliang Zou, Yunzhi Tan, Jiacong Zhou, Wu Li, Meihua The efficacy and safety of quinagolide in hyperprolactinemia treatment: A systematic review and meta-analysis |
title | The efficacy and safety of quinagolide in hyperprolactinemia treatment: A systematic review and meta-analysis |
title_full | The efficacy and safety of quinagolide in hyperprolactinemia treatment: A systematic review and meta-analysis |
title_fullStr | The efficacy and safety of quinagolide in hyperprolactinemia treatment: A systematic review and meta-analysis |
title_full_unstemmed | The efficacy and safety of quinagolide in hyperprolactinemia treatment: A systematic review and meta-analysis |
title_short | The efficacy and safety of quinagolide in hyperprolactinemia treatment: A systematic review and meta-analysis |
title_sort | efficacy and safety of quinagolide in hyperprolactinemia treatment: a systematic review and meta-analysis |
topic | Endocrinology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9902948/ https://www.ncbi.nlm.nih.gov/pubmed/36761195 http://dx.doi.org/10.3389/fendo.2023.1027905 |
work_keys_str_mv | AT zengyanyang theefficacyandsafetyofquinagolideinhyperprolactinemiatreatmentasystematicreviewandmetaanalysis AT huangqingliang theefficacyandsafetyofquinagolideinhyperprolactinemiatreatmentasystematicreviewandmetaanalysis AT zouyunzhi theefficacyandsafetyofquinagolideinhyperprolactinemiatreatmentasystematicreviewandmetaanalysis AT tanjiacong theefficacyandsafetyofquinagolideinhyperprolactinemiatreatmentasystematicreviewandmetaanalysis AT zhouwu theefficacyandsafetyofquinagolideinhyperprolactinemiatreatmentasystematicreviewandmetaanalysis AT limeihua theefficacyandsafetyofquinagolideinhyperprolactinemiatreatmentasystematicreviewandmetaanalysis AT zengyanyang efficacyandsafetyofquinagolideinhyperprolactinemiatreatmentasystematicreviewandmetaanalysis AT huangqingliang efficacyandsafetyofquinagolideinhyperprolactinemiatreatmentasystematicreviewandmetaanalysis AT zouyunzhi efficacyandsafetyofquinagolideinhyperprolactinemiatreatmentasystematicreviewandmetaanalysis AT tanjiacong efficacyandsafetyofquinagolideinhyperprolactinemiatreatmentasystematicreviewandmetaanalysis AT zhouwu efficacyandsafetyofquinagolideinhyperprolactinemiatreatmentasystematicreviewandmetaanalysis AT limeihua efficacyandsafetyofquinagolideinhyperprolactinemiatreatmentasystematicreviewandmetaanalysis |